- Home
- PSNL vs GNTA Comparison
PSNL vs GNTA Comparison
Compare PSNL & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- GNTA
- Stock Information
- Founded
- PSNL 2011
- GNTA 2014
- Country
- PSNL United States
- GNTA Italy
- Employees
- PSNL N/A
- GNTA N/A
- Industry
- PSNL Medical Specialities
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNL Health Care
- GNTA Health Care
- Exchange
- PSNL Nasdaq
- GNTA Nasdaq
- Market Cap
- PSNL 321.1M
- GNTA 67.4M
- IPO Year
- PSNL 2019
- GNTA 2021
- Fundamental
- Price
- PSNL $5.19
- GNTA $5.34
- Analyst Decision
- PSNL Strong Buy
- GNTA Strong Buy
- Analyst Count
- PSNL 4
- GNTA 1
- Target Price
- PSNL $6.81
- GNTA $25.00
- AVG Volume (30 Days)
- PSNL 439.4K
- GNTA 28.4K
- Earning Date
- PSNL 11-06-2024
- GNTA 01-01-0001
- Dividend Yield
- PSNL N/A
- GNTA N/A
- EPS Growth
- PSNL N/A
- GNTA N/A
- EPS
- PSNL N/A
- GNTA N/A
- Revenue
- PSNL $80,027,000.00
- GNTA N/A
- Revenue This Year
- PSNL $10.85
- GNTA N/A
- Revenue Next Year
- PSNL $8.77
- GNTA N/A
- P/E Ratio
- PSNL N/A
- GNTA N/A
- Revenue Growth
- PSNL 19.20
- GNTA N/A
- 52 Week Low
- PSNL $0.89
- GNTA $2.20
- 52 Week High
- PSNL $7.20
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- GNTA 56.89
- Support Level
- PSNL $4.54
- GNTA $4.89
- Resistance Level
- PSNL $5.35
- GNTA $6.20
- Average True Range (ATR)
- PSNL 0.30
- GNTA 0.70
- MACD
- PSNL 0.05
- GNTA -0.06
- Stochastic Oscillator
- PSNL 84.71
- GNTA 37.32
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.